JP2003529550A - リポソーム封入されたｄｎａ経口ワクチン - Google Patents
リポソーム封入されたｄｎａ経口ワクチンInfo
- Publication number
- JP2003529550A JP2003529550A JP2001527772A JP2001527772A JP2003529550A JP 2003529550 A JP2003529550 A JP 2003529550A JP 2001527772 A JP2001527772 A JP 2001527772A JP 2001527772 A JP2001527772 A JP 2001527772A JP 2003529550 A JP2003529550 A JP 2003529550A
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- group
- groups
- vaccine
- vaccine according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940126578 oral vaccine Drugs 0.000 title claims abstract description 12
- 239000002502 liposome Substances 0.000 claims abstract description 59
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 150000001767 cationic compounds Chemical class 0.000 claims abstract description 19
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 16
- 230000007704 transition Effects 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 32
- 229960005486 vaccine Drugs 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 125000006413 ring segment Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 6
- 150000002313 glycerolipids Chemical class 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000007900 aqueous suspension Substances 0.000 claims description 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 claims 1
- 125000002743 phosphorus functional group Chemical group 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 abstract description 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 46
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 14
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 12
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 12
- 239000008188 pellet Substances 0.000 description 11
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000002550 fecal effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000001294 propane Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- -1 trimethylammonio Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 241000212384 Bifora Species 0.000 description 1
- 241000402062 Dolphin rhabdovirus Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- HKUFIYBZNQSHQS-UHFFFAOYSA-N n-octadecyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC HKUFIYBZNQSHQS-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99307786 | 1999-10-01 | ||
| EP99307786.6 | 1999-10-01 | ||
| PCT/GB2000/003773 WO2001024773A1 (en) | 1999-10-01 | 2000-10-02 | Liposome-entrapped dna oral vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003529550A true JP2003529550A (ja) | 2003-10-07 |
| JP2003529550A5 JP2003529550A5 (https=) | 2007-12-06 |
Family
ID=8241653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001527772A Ceased JP2003529550A (ja) | 1999-10-01 | 2000-10-02 | リポソーム封入されたｄｎａ経口ワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7008791B1 (https=) |
| EP (1) | EP1217989B1 (https=) |
| JP (1) | JP2003529550A (https=) |
| KR (1) | KR100744237B1 (https=) |
| CN (1) | CN1196474C (https=) |
| AT (1) | ATE312599T1 (https=) |
| AU (1) | AU7540500A (https=) |
| CA (1) | CA2386024A1 (https=) |
| DE (1) | DE60024843T2 (https=) |
| ES (1) | ES2256043T3 (https=) |
| WO (1) | WO2001024773A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010514412A (ja) * | 2006-12-22 | 2010-05-06 | ソリューシオネス バイオテクノロジカス イノヴァシオン リミターダ | Ｄｎａ魚ワクチン |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2279127T3 (es) | 2002-07-05 | 2007-08-16 | Lipoxen Technologies Limited | Procedimiento para aumentar una respuesta inmunitaria de vacunacion de acido nucleico. |
| EP1628636A1 (de) * | 2003-05-09 | 2006-03-01 | Novosom AG | Injizierbare liposomale depots zum wirkstoffdelivery |
| JP4255396B2 (ja) * | 2004-03-19 | 2009-04-15 | 津田駒工業株式会社 | 水噴射式織機の水受け装置 |
| EP2146692A1 (en) * | 2007-03-19 | 2010-01-27 | Fresenius Kabi Oncology Limited | Proliposomal and liposomal compositions |
| CN101940320B (zh) * | 2010-08-06 | 2012-08-29 | 南昌大学 | 薄膜分散-动态高压微射流制备中链脂肪酸纳米脂质体 |
| CN101940321B (zh) * | 2010-08-06 | 2012-06-20 | 南昌大学 | 动态高压微射流-冻融法制备中链脂肪酸纳米脂质体 |
| EP2708134A1 (en) | 2012-09-17 | 2014-03-19 | Unilever N.V. | Dough compositions comprising a structured fat phase |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010748A1 (en) * | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2760193B1 (fr) * | 1997-02-28 | 1999-05-28 | Transgene Sa | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
-
2000
- 2000-10-02 JP JP2001527772A patent/JP2003529550A/ja not_active Ceased
- 2000-10-02 US US10/089,312 patent/US7008791B1/en not_active Expired - Fee Related
- 2000-10-02 WO PCT/GB2000/003773 patent/WO2001024773A1/en not_active Ceased
- 2000-10-02 KR KR1020027003922A patent/KR100744237B1/ko not_active Expired - Fee Related
- 2000-10-02 EP EP00964471A patent/EP1217989B1/en not_active Expired - Lifetime
- 2000-10-02 AT AT00964471T patent/ATE312599T1/de not_active IP Right Cessation
- 2000-10-02 ES ES00964471T patent/ES2256043T3/es not_active Expired - Lifetime
- 2000-10-02 AU AU75405/00A patent/AU7540500A/en not_active Abandoned
- 2000-10-02 DE DE60024843T patent/DE60024843T2/de not_active Expired - Lifetime
- 2000-10-02 CA CA002386024A patent/CA2386024A1/en not_active Abandoned
- 2000-10-02 CN CNB008134766A patent/CN1196474C/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010748A1 (en) * | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010514412A (ja) * | 2006-12-22 | 2010-05-06 | ソリューシオネス バイオテクノロジカス イノヴァシオン リミターダ | Ｄｎａ魚ワクチン |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE312599T1 (de) | 2005-12-15 |
| WO2001024773A1 (en) | 2001-04-12 |
| CA2386024A1 (en) | 2001-04-12 |
| US7008791B1 (en) | 2006-03-07 |
| KR20030011763A (ko) | 2003-02-11 |
| KR100744237B1 (ko) | 2007-07-30 |
| CN1196474C (zh) | 2005-04-13 |
| DE60024843T2 (de) | 2006-08-10 |
| EP1217989A1 (en) | 2002-07-03 |
| CN1376056A (zh) | 2002-10-23 |
| DE60024843D1 (de) | 2006-01-19 |
| AU7540500A (en) | 2001-05-10 |
| WO2001024773B1 (en) | 2001-08-16 |
| ES2256043T3 (es) | 2006-07-16 |
| EP1217989B1 (en) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100507660B1 (ko) | 리포좀 | |
| US6056938A (en) | Cationic lipids and the use thereof | |
| US6066331A (en) | Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers | |
| DE60310562T2 (de) | Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen | |
| US5876721A (en) | Vaccines | |
| CA2192597A1 (fr) | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament | |
| JPH09501169A (ja) | 小胞に生体高分子物質を高度に充填する方法 | |
| JPH06247842A (ja) | リポソーム組成物の製造方法 | |
| Bakouche et al. | Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition | |
| JP2001527052A (ja) | ポリアミドオリゴマー | |
| JP2002104993A (ja) | 抗腫瘍ワクチン | |
| JP2003529550A (ja) | リポソーム封入されたｄｎａ経口ワクチン | |
| CA1331860C (en) | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes | |
| JP3804452B2 (ja) | 肝炎治療剤 | |
| JP2003529550A5 (https=) | ||
| EP0713387B1 (en) | A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers | |
| US7381421B2 (en) | Liposomes | |
| JP2817883B2 (ja) | 高度に完全なリポソームおよびその製剤法と用途 | |
| JP2002509102A (ja) | リポマトリックス製剤 | |
| EP1361862B1 (en) | Liposome-mediated dna administration | |
| US20060062839A1 (en) | Efficient liposomal encapsulation under mild conditions | |
| WO2003057189A1 (en) | Efficient liposomal encapsulation under mild conditions | |
| JP2001089360A (ja) | Ｔリンパ球増殖反応の低下剤 | |
| JPWO1992004887A1 (ja) | 細胞障害性ｔ細胞の誘導方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071016 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20110125 |